At the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, three studies examined painful diabetic peripheral neuropathy (PDPN), spanning prognosis markers, neuromodulation, and immunologic targeted therapy.
Article Key Points
- UK CPRD cohort (n=52,844): PDPN associated with 24% higher mortality vs matched controls without PDPN (aHR 1.24)
- Mortality varied by ethnicity and treatment: opioids higher (aHR 1.19), gabapentin/pregabalin lower (aHR 0.93)
- 10 kHz SCS RCT: 79.4% pain response at 6 months vs 4.0% with CMM (p<0.001); sustained at 12 months
- 92% of CMM-arm patients crossed to SCS; sensory function also improved at 6 months (55% vs 25%, p=0.014)
- Eptinezumab (CGRP mAb) phase 2 trial: no significant pain reduction vs placebo (p=0.737); well tolerated
- Evidence status: conference abstracts; full results have not yet been peer-reviewed
PDPN and Mortality: National Cohort Reveals Risk and Ethnic Differences
Study design: Population-based retrospective cohort using the UK Clinical Practice Research Datalink (CPRD) Aurum database (2010-2023). Population: 52,844 adults with diabetes and PDPN, followed until death or study end. Annual PDPN prevalence was calculated for January 1 of each year, age- and sex-standardized, and stratified by ethnicity, region, and Index of Multiple Deprivation (IMD). Cox regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI); a 1:4 propensity score matching compared mortality between diabetes patients with and without PDPN.
Results: White patients were older (mean 61.4 years, ~53% male), while Black and Asian patients had higher female proportions. PDPN prevalence was higher in northern regions and more deprived areas, showing a socioeconomic gradient; in the most deprived areas, prevalence rose from 2,655 per 100,000 in 2010 to 4,064 per 100,000 in 2017, then declined to 3,523 per 100,000 in 2023.
During follow-up, 13,875 patients (26.2%) died. Compared with White patients, minority ethnic groups had lower mortality risk: Black (adjusted HR [aHR] 0.77), Mixed (aHR 0.62), Asian (aHR 0.77), and Other (aHR 0.66); patients with missing ethnicity had higher mortality (aHR 1.92).
After matching, 40,241 PDPN patients were compared with 160,798 non-PDPN controls. PDPN patients had higher mortality (1,190.8 vs 1,010.0 per 100,000 person-years), corresponding to a 24% increased mortality risk (aHR 1.24).
Mortality varied by treatment: opioids were associated with higher mortality (aHR 1.19), while gabapentin/pregabalin (aHR 0.93) and amitriptyline (aHR 0.87) were associated with lower mortality.
The authors noted these associations are not causal and that PDPN identifies a high-risk population requiring active management; ethnic differences suggest the need for targeted strategies to reduce health disparities.
10 kHz Spinal Cord Stimulation: Significant and Sustained Pain and Sensory Improvement
Study design: Multicenter randomized controlled trial in PDPN patients with lower limb pain visual analog score (VAS) ≥5 cm and modified Toronto Clinical Neuropathy Score (mTCNS) >5. Patients were randomized 1:1 to 10 kHz SCS plus conventional medical management (CMM) or CMM alone. Primary endpoints were pain responder rate (≥50% pain relief) and sensory function improvement (≥3-point mTCNS gain), assessed by blinded evaluators. Crossover to the other arm was allowed at 6 months; follow-up continued to 12 months.
Results: Of 91 randomized participants, 50 were assigned to CMM and 41 to SCS. At 6 months in worst-case analysis, the SCS arm primary pain responder rate was 79.4% (95% CI 62.1%-90.6%) versus 4.0% for CMM (95% CI 0.7%-13.4%; p<0.001). In per-protocol analysis, 93.1% (27/29) in the SCS arm and 0% (0/48) in the CMM arm were pain responders at 6 months (p<0.001).
At 6 months, sensory function improvement responder rate was 55% in the SCS arm (95% CI 37.5%-71.6%) versus 25% in the CMM arm (95% CI 14.9%-38.8%; p=0.014).
At 12 months, 28 of 29 (96.6%) original SCS-arm patients completed the visit; one withdrew because of pocket pain. No SCS patient elected to cross to CMM, while 92% of CMM-arm patients crossed to SCS. Of 44 patients who crossed over, 41 received permanent implants and 40 (97.6%) completed the 12-month visit.
Responder rates in both the original SCS arm and the crossover group were sustained at 12 months. mTCNS evaluates pinprick, temperature, light touch, vibration, and position sense. One patient (1.4%) had the device explanted because of implant-site pain; none were explanted for insufficient efficacy.
The authors noted this study provides the first pre-specified evidence that 10 kHz SCS can significantly improve sensory function in PDPN patients.
CGRP Monoclonal Antibody (Eptinezumab): Phase 2 Trial Did Not Reduce Pain
Study design: Investigator-initiated randomized, double-blind, placebo-controlled, multicenter phase 2 trial in adults aged 18-75 with type 1 or type 2 diabetes and PDPN. Inclusion required confirmed diabetic peripheral neuropathy (Toronto Consensus Neuropathy Score >5, abnormal DPNCheck, or abnormal nerve conduction study) and probable neuropathic pain by NeuPSIG criteria, with symmetric distal pain ≥6 months and weekly average pain intensity ≥4 on a 0-10 numerical rating scale (NRS). Participants were randomized 1:1, stratified by center and baseline pain intensity, to intravenous 300 mg eptinezumab or placebo at baseline and week 12, with follow-up to week 24. A 24-week open-label extension followed, with two 300 mg eptinezumab infusions at weeks 36 and 48. Primary efficacy was limited to the randomized double-blind period; safety assessment covered both phases with follow-up to week 56.
Results: 90 participants were randomized (eptinezumab n=47, placebo n=43). Baseline characteristics were balanced: age 61.7 vs 62.0 years, female 38% vs 40%, type 1 diabetes 26% vs 23%, diabetes duration 19.5 vs 17.8 years, and baseline mean NRS 5.9 vs 5.6.
The between-group difference in NRS change from baseline to week 24 was 0.14 (95% CI -0.68 to 0.95, p=0.737), with no statistically significant effect.
No major safety concerns were identified.
The authors noted that, in this randomized double-blind phase 2 trial, eptinezumab did not significantly reduce pain compared with placebo in PDPN patients and was well tolerated.
Conclusion
Three studies extended the clinical understanding of PDPN across prognostic markers, neuromodulation, and immunologic targeted therapy. The national cohort study identified a 24% increase in mortality risk associated with PDPN alongside ethnic and treatment-related differences, suggesting PDPN patients require more active comprehensive management. The 10 kHz SCS RCT demonstrated significant and sustained pain and sensory function improvement over 12 months, offering a potential new option for patients with drug-refractory PDPN. Although the eptinezumab phase 2 trial was negative, it provides important negative evidence for immune-targeted therapy in PDPN.